Annals of the Rheumatic Diseases
peer-reviewed scientific journal
The Annals of the Rheumatic Diseases is an international peer-reviewed medical journal. It is published by Elsevier on behalf of the European Alliance of Associations for Rheumatology and covers all aspects of rheumatology, including musculoskeletal conditions, arthritis, and connective tissue diseases. The journal publishes original research, reviews, recommendations, and various other articles, as well as abstracts from conferences. The journal was established in 1939, and operates under a hybrid subscription business model that enables open access. The editor-in-chief is Josef Smolen.
Change of ownership and publisher
Until end of 2024, the Annals of the Rheumatic Diseases were published by BMJ. After a change of ownership, EULAR became the sole owner of the journal. Elsevier is the new publisher starting in January 2025.
Abstracting and indexing
The journal is abstracted and indexed in the Science Citation Index Expanded, Index Medicus, Excerpta Medica, and BIOSIS Previews. According to the Journal Citation Reports, its 2023 impact factor is 20.3.
The journal has been cited most often by: Arthritis & Rheumatism, Annals of the Rheumatic Diseases, Rheumatology, Journal of Rheumatology, and Clinical and Experimental Rheumatology.
The public source identifies “Annals of the Rheumatic Diseases” as peer-reviewed scientific journal. This brief keeps that definition visible, then builds a research path around Annals, Rheumatic and Diseases.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Annals of the Rheumatic Diseases”, the useful work is to connect “peer-reviewed scientific journal” to the records capable of establishing context and consequence.
The date and method of observation matter as much as the stated conclusion, especially where classification or consensus has changed. The source revision retrieved here is dated Jun 9, 2025. The linked authority identifier is Q4767876. 6 of 6 selected statements include explicit references; 1 carry qualifiers and 0 use preferred rank. The first chronological checks are 1939, 2024, 2025 and 2023.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Annals of the Rheumatic Diseases”, its source revision and the description used here.
- Expand the search: follow Annals of the Rheumatic Diseases primary sources, Annals of the Rheumatic Diseases archive and Annals research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Annals of the Rheumatic Diseases”?
- Is the terminology current, historical or disputed?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Annals of the Rheumatic Diseases” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.